Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/5/2010

944)1,781,731412,141Total operating expenses

11,086,91311,295,12636,730,92529,436,138Loss from operations

(11,086,913)(11,295,126)(36,730,925)(29,436,138)Other expense, net

(625,235)(145,979)(1,119,252)(742,411)Net loss

$   (11,712,148)$   (11,441,105)$   (37,850,177)$   (30,178,549)Basic and diluted net lossper share(1)

$
(0.23)$
(0.23)$
(0.75)$
(0.63)Shares used to compute basic anddiluted net loss per share(1)

50,554,80350,364,49350,529,05048,189,177(1)  As a result of the issuance of 12,039,794 shares of common stock pursuant to a private placement in the first quarter of 2009, there is a lack of comparability in the per share amounts between the nine month periods presented.CADENCE PHARMACEUTICALS, INC.(a development stage company)CONDENSED BALANCE SHEETSSeptember 30,December 31,2010 2009 (unaudited)AssetsCurrent assets:Cash, cash equivalents and short-term investments

$
59,726,983$
82,006,153Restricted cash

1,150,0001,497,848Prepaid expenses and other current assets

213,981549,243Total current assets

61,090,96484,053,244Property and equipment, net

7,939,6518,300,529Restricted cash

189,738189,738Other assets

3,571,19519,708Total assets

$
72,791,548$
92,563,219Liabilities and Stockholders' Equity Current liabilities:Accounts payable

$
,308,973$
2,656,597Accrued liabilities

5,626,6617,739,527Current debt, less discount

736,1666,442,327Other current liabilities

-22,048Total current liabilities

7,671,80016,860,499Other liabilities

441,100640,208Long-term debt, less discount

17,833,972-Total stockholders' equity

46,844,67675,062,512Total liabilities and stockholders' equity

$
72,791,548$
92,563,219
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. and DUBLIN , Jan. ... the agreement with KRS Global Biotechnology, Inc. for the compounding, ... be compounded for shipment in the United States ... FDA approved Outsourcing Facility capable of compounding naltrexone tablets in ...
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... 8 The National Business Group on Health, a non-profit ... that Sally Welborn, Senior Vice President of Benefits at Walmart, ... , "We are thrilled to announce Sally,s election to our ... President of Human Resources at Coca-Cola Enterprises Inc. and Chairman ...
... , ... Technologies, Inc. , has been selected by the Blue Cross ... watchlist screening software for OFAC, OIG and EPLS and USA PATRIOT ... compliance software to BCBSA,s Chicago headquarters and its member Blue Cross ...
... , - May Set Stage for Treating Brain Damage ... researchers have shown that feeding amino acids to brain-injured animals restores ... effective treatment for cognitive impairments suffered by people with traumatic brain ... intervention can restore a proper balance of neurochemicals in the injured ...
... levels increase, so does depression, anxiety and panic disorder, ... Young adults with elevated levels of lead in their ... and panic disorders, a new study suggests. , Researchers ... who took part in the U.S. National Health and ...
... is defined as the pathological retrograde movement of ... disturbances which may be important in reflux are ... motility disorder in these patients is ineffective esophageal ... have been shown to be strongly associated with ...
... is unclear whether patients with soft tissue sarcoma can ... type of therapy, some of the patient,s own (autologous) ... generally re-implanted after a course of high-dose chemotherapy. At ... benefit compared to conventional chemotherapy. Owing to current gaps ...
Cached Medicine News:Health News:National Business Group on Health Elects Sally Welborn, Walmart Executive, to Board of Directors 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 3Health News:With Amino Acid Diet, Mice Improve After Brain Injury 2Health News:With Amino Acid Diet, Mice Improve After Brain Injury 3Health News:Lead Exposure May Affect Mental Health 2Health News:Are manometric findings different between the patients with erosive and nonerosive disease? 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 3Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 4
... Optimal canal flare index. A/P and lateral ... rotational stability. Proximal medial hole, humeral / ... joint translation. Rough textured proximal surface to ... rotational resistance in cement, six stem sizes, ...
...
...
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
Medicine Products: